23andMe Launches New Genetic Report on Osteoporosis

Core Insights - 23andMe Holding Co. has launched a new polygenic risk score (PRS) report for osteoporosis, aimed at helping customers understand their genetic risk and actionable lifestyle changes to mitigate it [1][5][6] Company Overview - 23andMe is a leading human genetics company focused on making the human genome accessible and beneficial for individuals [1][8] - The company has a commitment to developing genetic reports that impact women's health, with existing offerings including reports on breast cancer, gestational diabetes, and polycystic ovary syndrome (PCOS) [5] Osteoporosis Insights - Osteoporosis affects approximately 12.3 million Americans, with an additional 40 million having osteopenia, a less severe form of low bone density [2] - The condition is more prevalent in women and becomes more common with age, with risk factors including family history, body frame size, certain medications, and other health conditions [3][4] - Early diagnosis of osteoporosis is crucial as it is highly actionable, with medications available to slow bone loss and lifestyle changes that can help prevent falls [4] PRS Report Details - The osteoporosis PRS report utilizes a statistical model based on genetic data from 23andMe's proprietary research database, estimating the likelihood of developing osteoporosis by considering genetic markers, ancestry, and birth sex [5][6] - Genetics is estimated to account for approximately 60-80% of the variability in bone density [5] - The report does not cover all possible genetic variants or non-genetic factors that may influence osteoporosis risk [7]